| Similar Articles |
|---|
 |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors.   |
Chemistry World
October 19, 2015
Philippa Matthews |
BMS agrees $1.7bn immuno-oncology collaboration Bristol-Myers Squibb has entered into a worldwide license and collaboration with Five Prime Therapeutics to develop and commercialize Five Prime's colony stimulating factor 1 receptor (CSF1R) antibodies. |
Chemistry World
February 24, 2015
Phillip Broadwith |
B-MS bolsters immuno-oncology with pair of deals In a bid to bolster its pipeline of immuno-oncology drugs, Bristol-Myers Squibb has agreed to buy US biotech firm Flexus Biosciences in a deal worth up to $1.25 billion |
Chemistry World
July 3, 2015
Andy Extance |
Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Two new 'personalized' cancer drugs approved Two new drugs for the most deadly kind of skin cancer have been approved by the US Food and Drug Administration. The drugs are only effective in patients whose tumors express specific genetic mutations, which can be identified using a device approved alongside the drugs. |
The Motley Fool
November 18, 2004
Charly Travers |
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
Chemistry World
August 5, 2015
Rebecca Trager |
Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market |
Chemistry World
June 5, 2015
Rebecca Trager |
BMS sues executive for joining rival company Bristol-Myers Squibb has filed a lawsuit against a former executive who quit suddenly last month to work for a direct competitor, AstraZeneca. |
The Motley Fool
November 8, 2004
Charly Travers |
A Fantastic Cancer-Drug Deal Has Medarex hit the jackpot with MDX-010? Aside from the great financial terms, this deal is an important step in Medarex's transition from a research company to a company with commercial operations. |
Chemistry World
December 17, 2015
Sarah Houlton |
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. |
Chemistry World
January 11, 2012
Andrew Turley |
BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection. |
Pharmaceutical Executive
November 1, 2014
Josh Baxt |
2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin. |
Pharmaceutical Executive
November 1, 2013
Ben Comer |
2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters. |
Chemistry World
March 14, 2014
Phillip Broadwith |
Bristol-Myers Squibb to close Irish plant BMS tied the closure to 'changing market demand' for its products, along with efforts to optimize its manufacturing network. |
